Microwave-assisted synthesis and evaluation of antibacterial activity of novel 6-fluoroaryl-[1,2,4]triazolo[1,5-*a*]pyrimidines

Egor V. Verbitskiy,^{a,b,*} Svetlana A. Baskakova,^a Nikolay A. Rasputin,^a
Natal'ya A. Gerasimova,^c Polina G. Amineva,^c Natal'ya P. Evstigneeva,^c
Natal'ya V. Zil'berberg,^c Nikolay V. Kungurov,^c Marionella A. Kravchenko,^d
Sergey N. Skorniyakov,^d Gennady L. Rusinov,^{a,b} Oleg N. Chupakhin,^{a,b}
and Valery N. Charushin ^{a,b}

^a Postovsky Institute of Organic Synthesis, Ural Branch of the Russian Academy of Sciences,
S. Kovalevskoy Str. 22, Ekaterinburg, 620990, Russia

^bUral Federal University, Mira St. 19, Ekaterinburg, 620002, Russia

^cUral Research Institute for Dermatology, Venereology and Immunopathology,
Scherbakova St. 8, Ekaterinburg, 620076, Russia

^dUral Research Institute for Phthisiopulmonology, 22 Parts 'ezda St. 50,
Ekaterinburg, 620039, Russia

E-mail: Verbitsky@ios.uran.ru

DOI: <http://dx.doi.org/10.3998/ark.5550190.p009.731>

Abstract

A series of 6-fluoroaryl substituted [1,2,4]triazolo[1,5-*a*]pyrimidines have been synthesized by using the microwave-assisted Suzuki cross-coupling reaction from readily available 6-bromo-[1,2,4]triazolo[1,5-*a*]pyrimidine. The antimicrobial activity of new compounds has been evaluated *in vitro* against *Mycobacterium tuberculosis* H₃₇Rv and gram-negative (*Neisseria gonorrhoeae* ATCC 49226) bacteria.

Keywords: [1,2,4]triazolo[1,5-*a*]pyrimidines, Suzuki cross-coupling, microwave irradiation, antimycobacterial activity, anti-gonorrhea activity

Introduction

The need for the development of new antibacterial agents can hardly be overestimated. Such global scale phenomena as the emergence of multi-drug-resistance (MDR), and extensive drug-resistance (XDR), have raised the severe concern of the world healthcare community in the last few decades. The US Center for Disease Control and Prevention (CDC) has classified "high priority antibiotic-resistant bacteria" that include *Mycobacterium tuberculosis* (MDR, XDR), *Neisseria gonorrhoeae*,

Staphylococcus aureus (MRSA), *Clostridium difficile*, *Streptococcus pneumoniae*, *Klebsiella species*, *Acinetobacter*, *Campylobacter* and *Salmonella*.¹ This increased resistance demands the discovery and development of novel antimicrobial leads with high efficacy.²

Azoloazines belong to one of the most important groups of nitrogen-containing condensed heterocyclic systems.³ Being analogues of DNA purine bases, they can be regarded as plausible substrates for enzymatic biochemical processes.⁴ In particular, derivatives of [1,2,4]triazolo[4,3-*a*]pyrimidines have recently been reported as potential antibacterials.⁵⁻⁸ On the other hand, there are a few publications dealing with biological activities of [1,2,4]triazolo[1,5-*a*]pyrimidines as anxiolytic⁹ and antileukemia agents.^{10,11} Although 6-bromo-[1,2,4]triazolo[1,5-*a*]pyrimidine was first synthesized in 1961 by Makisumi,¹² no publications concerning the reactivity of this compound in the Suzuki cross-coupling have so far been reported in the literature.

A typical procedure for preparation of 6-substituted [1,2,4]triazolo[1,5-*a*]pyrimidines (**3**) is by condensation of 2*H*-[1,2,4]triazol-3-amine (**1**) with a 2-substituted malonaldehyde (**2**) or its synthetic equivalent (Scheme 1).^{9,13,14}

Scheme 1. Synthesis of 6-substituted [1,2,4]triazolo[1,5-*a*]pyrimidines (**3**) by condensation of 2*H*-[1,2,4]triazol-3-amine (**1**) with 2-substituted malondialdehydes (**2**)

It is known that fluorine-containing heterocycles, especially fluoroquinolones, have gained attention as effective antibacterial agents.¹⁵⁻¹⁹ We have recently elucidated how a fluorine atom (or CF₃-group), incorporating at various positions a 5-(fluoroaryl) substituent in 4-(hetero)aryl-pyrimidines can affect their antibacterial activity against *Mycobacterium tuberculosis* and other pathogenic strains such as *M. avium* and *M. terrae*.²⁰

In this communication we report the synthesis of novel 6-fluoroaryl substituted [1,2,4]triazolo[1,5-*a*]pyrimidines using microwave-assisted Suzuki cross-coupling, and present data on their antimicrobial activities *in vitro* against *Mycobacterium tuberculosis* H₃₇Rv and the gram-negative *Neisseria gonorrhoeae* ATCC 49226 bacteria.

Results and Discussion

It has been shown that 5-bromopyrimidines react smoothly with a number of (hetero)arylboronic and *trans*-2-styrylboronic acids under microwave irradiation conditions to give the corresponding Suzuki cross-coupling products in high yields.²⁰⁻²⁵

We have exploited this protocol for the synthesis of 6-phenyl- (**5a**) and 6-(fluoroaryl)-[1,2,4]triazolo[1,5-*a*]pyrimidines (**5b-j**). Indeed, compounds **5a-f** were obtained in good yields by reacting the readily-available 6-bromo-[1,2,4]triazolo[1,5-*a*]pyrimidine (**3**) with phenylboronic (**4a**) and various fluorinated phenylboronic acids (**4b-j**) under microwave irradiation, using 1,4-dioxane-H₂O (4:3) as solvent, and K₂CO₃ and Pd(PPh₃)₄, as catalyst (Scheme 2, Table 1).

Scheme 2. Synthesis of 6-phenyl- and 6-(fluorophenyl)-[1,2,4]triazolo[1,5-*a*]pyrimidines (**5a-j**)

Table 1. Characteristics of 6-aryl-[1,2,4]triazolo[1,5-*a*]pyrimidines (**5a-j**)

Entry	Compds	6-Substituent	Isolated	Mp (°C)
			Yield (%)	
1	5a	phenyl	75	166-168
2	5b	2-fluorophenyl	57	157
3	5c	3-fluorophenyl	67	200-202
4	5d	4-fluorophenyl	70	234
5	5e	2,4-difluorophenyl	73	187-188
6	5f	3,5-difluorophenyl	68	188-190
7	5g	2-(trifluoromethyl)phenyl	68	125-126
8	5h	3-(trifluoromethyl)phenyl	65	175
9	5i	4-(trifluoromethyl)phenyl	60	209-210
10	5j	3,5-bis(trifluoromethyl)phenyl	74	166-168

Unequivocal evidence for the structure of compounds **5a-j** was obtained by means of ^1H and ^{13}C NMR spectroscopy, as well as by X-ray crystallographic analysis carried out on 6-[3-(trifluoromethyl)phenyl][1,2,4]triazolo[1,5-*a*]pyrimidine (**5h**) (Fig. 1).

Figure 1. Mercury²⁶ representation of the X-ray crystal structure of **5h** with thermal ellipsoids of 50 % probability.

Table 2. *In vitro* antibacterial activity of 6-substituted [1,2,4]triazolo[1,5-*a*]pyrimidines (**3** and **5a-j**)

Compds.	Molecular Mass	Antibacterial activity (MIC), $\mu\text{g/mL}$	
		<i>Mycobacterium tuberculosis</i> H ₃₇ Rv	<i>Neisseria gonorrhoeae</i> ATCC 49226
3	199.01	3.1	>1000
5a	196.21	3.1	1000
5b	214.20	12.5	500
5c	214.20	6.2	1000
5d	214.20	12.5	1000
5e	232.19	12.5	500
5f	232.19	12.5	500
5g	264.21	12.5	500
5h	264.21	12.5	500
5i	264.21	12.5	500
5j	332.21	1.5	1000
Isoniazid	137.14	0.1	-
Pyrazinamide	123.12	12.5	-
Ceftriaxone	554.58	-	0.015
Azithromycin	748.98	-	0.5
Spectinomycin	332.35	-	32

Azolopyrimidines **3** and **5a-j** were screened for their activity *in vitro* against *Mycobacterium tuberculosis* H₃₇Rv and gram-negative (*Neisseria gonorrhoeae* ATCC 49226) bacteria, and the data on the minimal inhibitory concentrations (MICs) of these compounds are summarized in Table 2. Clinical drugs Isoniazid, Pyrazinamide and Azithromycin were taken as the reference compounds.

The antibacterial assay data show that the investigated [1,2,4]triazolo[1,5-*a*]pyrimidines showed moderate activity against *Mycobacterium tuberculosis* H₃₇Rv *in vitro*. Displacement of the bromo atom of the pyrimidine ring with a fluoroaryl substituent leads to a reduction in antimycobacterial activity. On the other hand, variation of the fluoroaryl moiety in azolopyrimidines **5** has a negligible effect on their anti-gonorrheal activity, and the unexciting values of MIC, not exceeding 500 µg/mL, have been obtained for compounds **5b,e-i**. Unfortunately, the poor results of antibacterial screening do not allow any conclusions to be drawn on structure-activity relationships.

Conclusions

We have demonstrated a convenient method for the synthesis of new 6-aryl substituted [1,2,4]triazolo[1,5-*a*]pyrimidines, including fluorinated derivatives. Antibacterial studies have shown that fluoroaryl substituted derivatives are poorly active against *Mycobacterium tuberculosis* H₃₇Rv and gram-negative (*Neisseria gonorrhoeae* ATCC 49226) bacteria, while 6-bromo- and 6-phenyl-substituted [1,2,4]triazolo[1,5-*a*]pyrimidines have a higher bacteriostatic effect, comparable with the first-line antituberculosis drug (Pyrazinamide).

Being not active enough to be therapeutics, compounds of this family can, nevertheless, be regarded as appropriate for further studies, aimed at development of effective agents to combat resistant forms of tuberculosis.

Experimental Section

General Information. All reagents and solvents were obtained from commercial sources and dried by using the standard procedures before use. 6-Bromo-[1,2,4]triazolo[1,5-*a*]pyrimidine was synthesized as described previously.¹² Solvents (1,4-dioxane and H₂O) for the microwave-assisted Suzuki cross-coupling reaction were deoxygenated by bubbling argon for 1h.

The ¹H, ¹⁹F, and ¹³C NMR spectra were recorded on a Bruker DRX-400 and Avance-500 instruments, using Me₄Si and C₆F₆ as internal standards. Elemental analyses were carried on a Eurovector EA 3000 automated analyzer. Melting points were determined on Boetius combined heating stages and were not corrected.

The GC-MS analyses of all samples were carried out using an Agilent GC 7890A MS 5975C Inert XL EI/CI GC-MS spectrometer with a quadrupole mass-spectrometric detector with electron ionization (70 eV).

Column chromatography was carried out using Alfa Aesar silica gel 0.040-0.063 mm (230–400 mesh). The progress of reactions and the purity of compounds were checked by TLC on Sorbfil plates (Russia), in which the spots were visualized with UV light (λ 254 or 365 nm).

Microwave experiments were carried out in a Discover unimodal microwave system (CEM, USA) with a working frequency of 2.45 GHz and the microwave radiation power ranged from 0 to 300 W. The reactions were carried out in a 10 mL reaction tube with the hermetic Teflon cork. The reaction temperature was monitored, using an inserted IR sensor by the external surface of the reaction vessel.

A suitable crystal of **5h** was selected and XRD analysis was performed on a Xcalibur diffractometer using standard procedure (MoK α graphite-monochromated irradiation, ω -scanning with 1° steps). Compound **5h** was solved and refined by using Olex2 program.²⁷ Non-hydrogen atoms were refined in anisotropic approximation; H-atoms were refined in isotropic approximation in riding model. The X-ray crystallography data for structure **5h** reported in this paper have been deposited with Cambridge Crystallography Data Centre as supplementary publications CCDC no. 1483333 for **5h**. These data can be obtained free of charge from the Cambridge Crystallographic Data Centre via www.ccdc.cam.ac.uk/data_request/cif.

General procedure for the synthesis of 6-aryl-[1,2,4]triazolo[1,5-*a*]pyrimidine derivatives (5a-j). A solution of K₂CO₃ (346 mg, 2.5 mmol) in H₂O (3 mL) was added to a mixture of a 6-bromo-[1,2,4]triazolo[1,5-*a*]pyrimidine (**3**) (201 mg, 1.0 mmol), arylboronic (**4a-j**) acid (1.2 mmol) and Pd(PPh₃)₄ (58 mg, 5 mol %) in 1,4-dioxane (4 mL). The resulting mixture was irradiated in a microwave apparatus at 165 °C (250 W) for 20 min. After that solvent was distilled off *in vacuo*, and the residue was purified by flash column chromatography (hexane/ethyl acetate, 1:3) to afford the desired cross-coupling products (**5a-j**).

6-Phenyl-[1,2,4]triazolo[1,5-*a*]pyrimidine (5a). Yield 75%, white solid, mp 166-168 °C. ¹H NMR (500 MHz, DMSO-*d*₆): δ = 9.79 (d, *J* = 2.5 Hz, 1H), 9.29 (d, *J* = 2.5 Hz, 1H), 8.72 (s, 1H), 7.91-7.87 (m, 2H), 7.58-7.54 (m, 2H), 7.49 (ddd, *J* = 7.4, 3.8, 1.2 Hz, 1H) ppm. ¹³C NMR (126 MHz, DMSO-*d*₆): δ = 156.3, 154.9, 154.0, 134.1, 132.8, 129.2, 128.7, 127.3, 123.9 ppm. GC *t*_R 22.39 min; MS *m/z* (rel intensity) 196 (M⁺, 100). Anal. Calcd for C₁₁H₈N₄ (196.21): C 67.34, H 4.11, N 28.55. Found: C 67.33, H 4.22, N 28.28.

6-(2-Fluorophenyl)-[1,2,4]triazolo[1,5-*a*]pyrimidine (5b). Yield 57%, white solid, mp 157 °C. ¹H NMR (500 MHz, DMSO-*d*₆): δ = 9.70 (d, *J* = 1.7 Hz, 1H), 9.12 (d, *J* = 1.9 Hz, 1H), 8.76 (s, 1H), 7.78 (td, *J* = 7.9, 1.5 Hz, 1H), 7.60-7.54 (m, 1H), 7.47-7.38 (m, 2H) ppm. ¹³C NMR (126 MHz, DMSO-*d*₆): δ = 159.3 (d, ¹*J*_{C,F} = 247.0 Hz), 156.5, 155.8 (d, ³*J*_{C,F} = 3.9 Hz), 153.8, 136.1 (d, ⁴*J*_{C,F} = 3.2 Hz), 131.2 (d, ⁴*J*_{C,F} = 2.7 Hz), 131.2 (s), 125.3 (d, ⁴*J*_{C,F} = 3.5 Hz), 120.8 (d, ²*J*_{C,F} = 13.3 Hz), 118.9, 116.2 (d, ²*J*_{C,F} = 21.7 Hz) ppm. ¹⁹F NMR (470.5 MHz, DMSO-*d*₆): δ = 44.93-44.85 (m, 1F). GC *t*_R 22.09 min; MS *m/z* (rel intensity) 214 (M⁺, 100). Anal. Calcd for C₁₁H₇FN₄ (214.20): C 61.68, H 3.29, N 26.16. Found: C 61.64, H 3.45, N 25.92.

6-(3-Fluorophenyl)-[1,2,4]triazolo[1,5-*a*]pyrimidine (5c). Yield 67%, white solid, mp 200-202 °C. ¹H NMR (500 MHz, DMSO-*d*₆): δ = 9.86 (d, *J* = 2.5 Hz, 1H), 9.32 (d, *J* = 2.5 Hz, 1H), 8.74 (s, 1H), 7.84-7.80 (m, 1H), 7.76 (d, *J* = 7.8 Hz, 1H), 7.60 (td, *J* = 8.0, 6.3 Hz, 1H), 7.33 (td, *J* = 8.3, 1.9 Hz, 1H) ppm. ¹³C NMR (126 MHz, DMSO-*d*₆): δ = 162.6 (d, ¹*J*_{C,F} = 243.7 Hz), 156.5, 154.8, 154.1, 135.15 (d, ³*J*_{C,F} = 8.4 Hz), 134.6, 131.2 (d, ³*J*_{C,F} = 8.6 Hz), 123.3 (d, ⁴*J*_{C,F} = 2.7 Hz), 122.6 (d, ⁴*J*_{C,F} = 2.3 Hz), 115.5 (d, ²*J*_{C,F} = 21.1 Hz), 114.1 (d, ²*J*_{C,F} = 23.1 Hz) ppm. ¹⁹F NMR (470.5 MHz, DMSO-*d*₆): 50.47 (ddd, 1F, *J* = 10.5, 8.9, 6.2 Hz). GC *t*_R 22.22 min; MS *m/z* (rel intensity) 214 (*M*⁺, 100). Anal. Calcd for C₁₁H₇FN₄ (214.20): C 61.68, H 3.29, N 26.16. Found: C 61.51, H 3.36, N 25.97.

6-(4-Fluorophenyl)-[1,2,4]triazolo[1,5-*a*]pyrimidine (5d). Yield 70%, white solid, mp 234 °C. ¹H NMR (500 MHz, DMSO-*d*₆): δ = 9.78 (d, *J* = 2.5 Hz, 1H), 9.27 (d, *J* = 2.5 Hz, 1H), 8.72 (s, 1H), 8.03-7.86 (m, 2H), 7.50-7.31 (m, 2H) ppm. ¹³C NMR (126 MHz, DMSO-*d*₆): δ = 162.6 (d, ¹*J*_{C,F} = 246.3 Hz), 156.3, 154.8, 153.9, 134.1, 129.5 (d, ³*J*_{C,F} = 8.4 Hz), 129.3 (d, ⁴*J*_{C,F} = 3.1 Hz), 123.0, 116.1 (d, ²*J*_{C,F} = 21.7 Hz) ppm. ¹⁹F NMR (470.5 MHz, DMSO-*d*₆): 49.19 (tt, 1F, *J* = 8.9, 5.4 Hz). GC *t*_R 22.39 min; MS *m/z* (rel intensity) 214 (*M*⁺, 100). Anal. Calcd for C₁₁H₇FN₄ (214.20): C 61.68, H 3.29, N 26.16. Found: C 61.54, H 2.67, N 25.91.

6-(2,4-Difluorophenyl)-[1,2,4]triazolo[1,5-*a*]pyrimidine (5e). Yield 73%, white solid, mp 187-188 °C. ¹H NMR (500 MHz, DMSO-*d*₆): δ = 9.69 (d, *J* = 1.7 Hz, 1H), 9.09 (t, *J* = 2.0 Hz, 1H), 8.76 (s, 1H), 7.84 (td, *J* = 8.8, 6.5 Hz, 1H), 7.58 – 7.47 (m, 1H), 7.33 (td, *J* = 8.5, 1.8 Hz, 1H) ppm. ¹³C NMR (126 MHz, DMSO-*d*₆): δ = 163.7 (d, ²*J*_{C,F} = 12.3 Hz), 161.7 (d, ²*J*_{C,F} = 12.3 Hz), 159.5 (dd, ¹*J*_{C,F} = 249.9, ²*J*_{C,F} = 12.6 Hz), 156.5, 155.7 (d, ⁴*J*_{C,F} = 3.7 Hz), 153.8, 136.2 (d, ⁴*J*_{C,F} = 2.7 Hz), 132.6 (dd, ³*J*_{C,F} = 10.0, ⁴*J*_{C,F} = 3.9 Hz), 117.5 (dd, ³*J*_{C,F} = 13.7, ⁴*J*_{C,F} = 3.7 Hz), 112.5 (dd, ²*J*_{C,F} = 21.5, ⁴*J*_{C,F} = 3.7 Hz), 104.8 (t, ²*J*_{C,F} = 26.3 Hz) ppm. ¹⁹F NMR (470.5 MHz, DMSO-*d*₆): 54.45-53.50 (m, 1F), 49.75 (dd, 1F, *J* = 18.8, 9.1 Hz). GC *t*_R 21.72 min; MS *m/z* (rel intensity) 232 (*M*⁺, 100). Anal. Calcd for C₁₁H₆F₂N₄ (232.19): C 56.90, H 2.60, N 24.13. Found: C 56.75, H 2.67, N 23.94.

6-(3,5-Difluorophenyl)-[1,2,4]triazolo[1,5-*a*]pyrimidine (5f). Yield 68%, white solid, mp 188-190 °C. ¹H NMR (500 MHz, DMSO-*d*₆): δ = 9.91 (d, *J* = 2.5 Hz, 1H), 9.35 (d, *J* = 2.5 Hz, 1H), 8.76 (s, 1H), 7.84-7.68 (m, 2H), 7.38 (tt, *J* = 9.1, 2.2 Hz, 1H) ppm. ¹³C NMR (126 MHz, DMSO-*d*₆): δ = 162.9 (dd, ¹*J*_{C,F} = 246.1, ³*J*_{C,F} = 13.7 Hz), 156.7, 154.6, 154.2, 136.4 (t, ²*J*_{C,F} = 10.6 Hz), 135.1, 121.5 (t, ⁴*J*_{C,F} = 2.6 Hz), 110.5 (dd, ²*J*_{C,F} = 20.4, ⁴*J*_{C,F} = 6.7 Hz), 104.0 (t, ²*J*_{C,F} = 25.9 Hz) ppm. ¹⁹F NMR (470.5 MHz, DMSO-*d*₆): 54.77-53.38 (m, 2F). GC *t*_R 21.65 min; MS *m/z* (rel intensity) 232 (*M*⁺, 100). Anal. Calcd for C₁₁H₆F₂N₄ (232.19): C 56.90, H 2.60, N 24.13. Found: C 56.76, H 2.56, N 23.97.

6-(2-Trifluoromethylphenyl)-[1,2,4]triazolo[1,5-*a*]pyrimidine (5g). Yield 68%, white solid, mp 125-126 °C. ¹H NMR (500 MHz, DMSO-*d*₆): δ = 9.61 (d, *J* = 2.3 Hz, 1H), 8.88 (d, *J* = 1.8 Hz, 1H), 8.77 (s, 1H), 7.94 (d, *J* = 7.8 Hz, 1H), 7.83 (t, *J* = 7.5 Hz, 1H), 7.75 (t, *J* = 7.7 Hz, 1H), 7.67 (d, *J* = 7.6 Hz, 1H) ppm. ¹³C NMR (126 MHz, DMSO-*d*₆): δ = 156.6, 154.8 (d, ¹*J*_{C,F} = 223.4 Hz), 136.2, 133.4, 132.7, 131.9 (d, ⁴*J*_{C,F} = 1.6 Hz), 129.7, 128.0 (q, ²*J*_{C,F} = 29.4 Hz), 127.2, 126.3 (q, ⁴*J*_{C,F} = 5.2 Hz), 123.91 (q, ¹*J*_{C,F} = 274.0 Hz), 122.5 ppm. ¹⁹F NMR (470.5 MHz, DMSO-*d*₆): 106.92

(s, CF₃). GC *t_R* 21.27 min; MS *m/z* (rel intensity) 264 (M⁺, 100). Anal. Calcd for C₁₂H₇F₃N₄ (264.21): C 54.55, H 2.67, N 21.21. Found: C 54.61, H 2.80, N 21.05.

6-(3-Trifluoromethylphenyl)-[1,2,4]triazolo[1,5-*a*]pyrimidine (5h). Yield 65%, white solid, mp 175 °C. ¹H NMR (500 MHz, DMSO-*d*₆): δ = 9.94 (d, *J* = 2.5 Hz, 1H), 9.36 (d, *J* = 2.5 Hz, 1H), 8.75 (s, 1H), 8.29 (s, 1H), 8.21 (d, *J* = 7.6 Hz, 1H), 7.85 (d, *J* = 7.8 Hz, 1H), 7.79 (t, *J* = 7.7 Hz, 1H) ppm. ¹³C NMR (126 MHz, DMSO-*d*₆): δ = 156.6, 154.9, 154.1, 135.0, 134.1, 131.4, 130.2, 130.0 (d, ²*J*_{C,F} = 31.8 Hz), 125.2 (dd, ³*J*_{C,F} = 7.1, ⁴*J*_{C,F} = 3.5 Hz), 124.1 (q, ⁴*J*_{C,F} = 3.6 Hz), 124.05 (q, ¹*J*_{C,F} = 272.7 Hz), 122.5 ppm. ¹⁹F NMR (470.5 MHz, DMSO-*d*₆): 101.62 (s, CF₃). GC *t_R* 22.05 min; MS *m/z* (rel intensity) 264 (M⁺, 100). Anal. Calcd for C₁₂H₇F₃N₄ (264.21): C 54.55, H 2.67, N 21.21. Found: C 54.53, H 2.56, N 21.04.

6-(4-Trifluoromethylphenyl)-[1,2,4]triazolo[1,5-*a*]pyrimidine (5i). Yield 60%, white solid, mp 209-210 °C. ¹H NMR (500 MHz, DMSO-*d*₆): δ = 9.92 (d, *J* = 2.5 Hz, 1H), 9.34 (d, *J* = 2.5 Hz, 1H), 8.76 (s, 1H), 8.13 (d, *J* = 8.2 Hz, 2H), 7.92 (d, *J* = 8.3 Hz, 2H) ppm. ¹³C NMR (126 MHz, DMSO-*d*₆): δ = 155.7 (d, ¹*J*_{C,F} = 228.8 Hz), 154.2, 137.1, 135.1, 128.9 (q, ²*J*_{C,F} = 32.1 Hz), 128.2, 126.0 (q, ⁴*J*_{C,F} = 3.7 Hz), 124.1 (q, ¹*J*_{C,F} = 272.1 Hz), 122.5 ppm. ¹⁹F NMR (470.5 MHz, DMSO-*d*₆): 101.50 (s, CF₃). GC *t_R* 22.35 min; MS *m/z* (rel intensity) 264 (M⁺, 100). Anal. Calcd for C₁₂H₇F₃N₄ (264.21): C 54.55, H 2.67, N 21.21. Found: C 54.41, H 2.61, N 21.08.

6-[3,5-Bis-(trifluoromethyl)phenyl]-[1,2,4]triazolo[1,5-*a*]pyrimidine (5j). Yield 74%, white solid, mp 166-168 °C. ¹H NMR (500 MHz, DMSO-*d*₆): δ = 10.07 (d, *J* = 2.5 Hz, 1H), 9.45 (d, *J* = 2.5 Hz, 1H), 8.78 (s, 1H), 8.64 (s, 2H), 8.22 (s, 1H) ppm. ¹³C NMR (126 MHz, DMSO-*d*₆): δ = 156.0 (d, ¹*J*_{C,F} = 220.6 Hz), 154.2, 135.9, 135.8, 131.1 (q, ²*J*_{C,F} = 33.1 Hz), 128.4 (d, ⁴*J*_{C,F} = 2.8 Hz), 123.2 (q, ¹*J*_{C,F} = 273.1 Hz), 122.1 (d, ³*J*_{C,F} = 7.5 Hz), 122.1, 121.2 ppm. ¹⁹F NMR (470.5 MHz, DMSO-*d*₆): 101.48 (s, 2 CF₃). GC *t_R* 22.70 min; MS: *m/z* (rel intensity) 332 (M⁺, 100). Anal. Calcd for C₁₃H₆F₆N₄ (332.21): C 47.00, H 1.82, N 16.86. Found: C 47.13, H 1.98, N 16.71.

Antimycobacterial assay.

To evaluate the inhibitory efficiency of molecules on *Mycobacterium tuberculosis* (MTB), *M. tuberculosis* H₃₇Rv, which is susceptible to all classical antituberculosis drugs, was used. The minimal inhibitory concentration (MIC) for *M. tuberculosis* H₃₇Rv for each compound was determined by a micro broth dilution method. All molecules tested were dissolved in dimethylsulfoxide and their 1/2 dilutions were prepared in 5 mL tubes using Löwenstein-Jensen medium. A few colonies from freshly grown *M. tuberculosis* H₃₇Rv were suspended in Löwenstein-Jensen medium to obtain 1.0 McFarland turbidity and diluted ten times using the same medium and the tubes were incubated at 37 °C medium with a different concentration of the tested molecule and to a positive control tube containing only clear growth medium. After 24 hours the tubes were placed in a vertical position and the free edge of the buried 0.3 mL of the substance in the test compounds concentrations: 12.5, 6.2, 3.1, 1.5, 0.7, 0.37, 0.15 µg/mL. The tubes were then placed in an thermostat at a temperature of 37 °C and incubated for 10 days. Growth estimate for the MTB were determined by standard methods, where the appearance of zones of growth retardation MTB (over 10 mm) indicated the presence of tuberculostatic properties in concentration of the compounds under study. Penetration size stunting MTB (in mm) is

proportional to the degree of tuberculostatic activity. Growth delay of 100 mm or more is considered as a complete growth inhibition MTB. The multi-drug-resistant (MDR) tuberculosis strain have been isolated from tuberculosis patients in Ural Research Institute for Phthisiopulmonology (Russia). The minimal inhibitory concentrations against *Mycobacterium avium*, *Mycobacterium terrae*, and MDR tuberculosis strains were evaluated similarly.

Anti-gonorrhea activity assay.

The two fold serial dilution technique recommended by Clinical and Laboratory Standards Institute (CLSI)²⁸ was used to evaluate the inhibitory efficiency of molecules on *Neisseria gonorrhoeae*. The medium for testing *Neisseria gonorrhoeae* consists of GC agar to which a 1% defined growth supplement. Adjust the density of the suspension to contain 10⁸ CFU/mL by comparison with a 0.5 McFarland turbidity standard. For suspension using colonies from an overnight (20- to 24-hour) chocolate agar plate incubated in 5% CO₂ 36±1°. Dilute this suspension 1:10 in Muller-Hinton to give 10⁷ CFU/mL. The test compounds concentrations: 1000, 500, 250, 125, 62.5, 31.2, 15.0, 7.5, 3.8, 1.9, 0.99 µg/mL (solvent – DMSO, diluent – H₂O and GC agar base).

Acknowledgements

The research was financially supported by the Russian Science Foundation (Project No. 15-13-00077).

References

1. Chaudhary, A. S.; Jin, J.; Chen, W.; Tai, P. C.; Wang, B. *Bioorg. Med. Chem.* **2015**, *23*, 105. <http://dx.doi.org/10.1016/j.bmc.2014.11.017>
2. Rane, R. A.; Naphade, S. S.; Bangalore, P. K.; Palkar, M. B.; Shaikh, M. S.; Karpoomath, R. *Bioorg. Med. Chem. Lett.* **2014**, *24*, 3079 and references cited therein. <http://dx.doi.org/10.1016/j.bmcl.2014.05.018>
3. Li, J. J. *Heterocyclic Chemistry in Drug Discovery*; Wiley & Sons, 2013; p. 720. ISBN: 978-1-118-14890-7.
4. Corey, E. J.; Kürti, L.; Czako, B. *Molecules and Medicine*; Wiley & Sons, 2008; p. 272. ISBN: 978-0-470-26096-8.
5. Prakash, O.; Bhardwaj, V.; Kumar, R.; Tyagi, P.; Aneja, K. R. *Eur. J. Med. Chem.* **2004**, *39*, 1073. <http://dx.doi.org/10.1016/j.ejmech.2004.06.011>

6. Kumar, R.; Nair, R. R.; Dhiman, S. S.; Sharma, J.; Prakash, O. *Eur. J. Med. Chem.* **2009**, *44*, 2260.
<http://dx.doi.org/10.1016/j.ejmech.2008.06.004>
7. Khera, M. K.; Cliffe, I. A.; Mathur, T.; Prakash, O. *Bioorg. Med. Chem. Lett.* **2011**, *21*, 2887.
<http://dx.doi.org/10.1016/j.bmcl.2011.03.075>
8. Krishnaraj, T.; Muthusubramanian, S. *J. Heterocyc. Chem.* **2014**, *51*, E68.
<http://dx.doi.org/10.1002/jhet.1806>
9. Dusza, J. P.; Hardy, R. A. Jr.; Albright, J. D. (1980) Patent US 4209621.
10. Li, Y.; Shen, M.; Zhang, Z.; Luo, J.; Pan, X.; Lu, X.; Long, H.; Wen, D.; Zhang, F.; Leng, F.; Li, Y.; Tu, Z.; Ren, X.; Ding, K. *J. Med. Chem.* **2012**, *55*, 10033.
<http://dx.doi.org/10.1021/jm301188x>
11. Ren, X.; Pan, X.; Zhang, Z.; Wang, D.; Lu, X.; Li, Y.; Wen, D.; Long, H.; Luo, J.; Feng, Y.; Zhuang, X.; Zhang, F.; Liu, J.; Leng, F.; Lang, X.; Bai, Y.; She, M.; Tu, Z.; Pan, J.; Ding, K. *J. Med. Chem.* **2013**, *56*, 879.
<http://dx.doi.org/10.1021/jm301581y>
12. Makisumi, Y. *Chem. Pharm. Bull.* **1961**, *9*, 808.
13. Petrich, S. A.; Qian, Z.; Santiago, L. M.; Gupton, J. T.; Sikorski, J. A. *Heterocycles* **1995**, *40*, 729.
<http://dx.doi.org/10.3987/COM-94-S61>
14. Henrich, M.; Weil, T.; Hechenberger, M.; Müller, S.; Kauss, V.; Zembiro, R.; Erdmane, E. Smits, G. (2011) Patent WO 2011/015343 A1.
15. Nosova, E. V.; Mochulskaya, N. N.; Kotovskaya, S.K.; Lipunova, G. N.; Charushin, V.N. *Heteroatom Chem.* **2006**, *17*, 579.
<http://dx.doi.org/10.1002/hc.20281>
16. Zhou, Y.; Wang, J.; Gu, Z.; Wang, S.; Zhu, W.; Aceña, J. L.; Soloshonok, V.A.; Izawa, K.; Liu, H. *Chem. Rev.* **2016**, *116*, 422.
<http://dx.doi.org/10.1021/acs.chemrev.5b00392>
17. V. N. Charushin, E. V., Nosova, G. N. Lipunova, O. N. Chupakhin, Fluoroquinolones: Synthesis and Application, Fizmatlit, Moscow, 2013.
18. V. N. Charushin, G. N. Lipunova, E. V. Nosova, O. N. Chupakhin, Fluoroquinolones: Synthesis and Application, in: V. Nenajdenko (Ed.), Fluorine in Heterocyclic Chemistry, Springer International Publishing, New York, 2014, p. 111-179.
19. Asif, M. *Chemistry International* **2015**, *1*, 134.
20. Verbitskiy, E. V.; Baskakova, S. A.; Kravchenko, M. A.; Skorniyakov, S. N.; Rusinov, G. L.; Chupakhin, O. N.; Charushin, V. N. *Bioorg. Med. Chem.* **2016**, *in press*.
<http://dx.doi.org/10.1016/j.bmc.2016.06.020>
21. Verbitskiy, E. V.; Cheprakova, E. M.; Slepukhin, P. A.; Kodess, M. I.; Ezhikova, M. A.; Pervova, M. G.; Rusinov, G. L.; Chupakhin, O. N.; Charushin, V.N. *Tetrahedron* **2012**, *68*, 5445.
<http://dx.doi.org/10.1016/j.tet.2012.04.095>

22. Verbitskiy, E. V.; Rusinov, G. L.; Charushin, V. N.; Chupakhin, O. N.; Cheprakova, E. M.; Slepukhin, P. A.; Pervova, M. G.; Ezhikova, M. A.; Kodess, M.I. *Eur. J. Org. Chem.* **2012**, 6612.
<http://dx.doi.org/10.1002/ejoc.201201035>
23. Kravchenko, M. A.; Verbitskiy, E. V.; Medvinskiy, I. D.; Rusinov, G.L.; Charushin, V.N. *Bioorg. Med. Chem. Lett.* **2014**, 24, 3118.
<http://dx.doi.org/10.1016/j.bmcl.2014.05.006>
24. Cheprakova, E. M.; Verbitskiy, E. V.; Ezhikova, M. A.; Kodess, M. I.; Pervova, M. G.; Slepukhin, P. A.; Toporova, M. S.; Kravchenko, M. A.; Medvinskiy, I. D.; Rusinov, G. L.; Charushin, V. N. *Russ. Chem. Bull.* **2014**, 63, 1350.
<http://dx.doi.org/10.1007/s11172-014-0602-y>
25. Verbitskiy, E. V.; Cheprakova, E. M.; Slepukhin, P. A.; Kravchenko, M. A.; Skorniyakov, S. N.; Rusinov, G. L.; Chupakhin, O.N.; Charushin, V.N. *Eur. J. Med. Chem.* **2015**, 97, 225.
<http://dx.doi.org/10.1016/j.ejmech.2015.05.007>
26. Mercury 3.3, available from <http://www.ccdc.cam.ac.uk/mercury/>.
27. Dolomanov, O. V.; Bourhis, L. J.; Gildea, R. J. ; Howard, J. A. K.; Puschmann, H. *J. Appl. Cryst.* **2009**, 42, 339.
[DOI: 10.1107/S0021889808042726](https://doi.org/10.1107/S0021889808042726)
28. Clinical and Laboratory Standards Institute. *Performance Standards for Antimicrobial Susceptibility Testing; Twenty-Fourth Informational Supplement*; Clinical and Laboratory Standards Institute: Wayne, PA, **2014**. (<http://www.cdc.gov/std/gonorrhea/arg/b88-feb-2005.pdf>).